Comparison of treatment results in children with non-high risk acute lymphoblastic leukaemia treated according to ALL-BFM 90 and ALL-IC BFM 2002 regimens – single centre preliminary experience  by Zając, Olga et al.
Comparison of treatment results in children with 
non-high risk acute lymphoblastic leukaemia treated 
according to ALL-BFM 90 and ALL-IC BFM 2002 
regimens – single centre preliminary experience
Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak
Klinika Onkologii, Hematologii i Transplantologii Pediatrycznej, Poznań, Polska
Proceedings from II Oncology Congress, Poznań 25–28.10.2007.
Summary
 Background Acute lymphoblastic leukaemia (ALL) represents about 30% of cancer in children 
and thus is the most common childhood malignancy. Despite the great progress, 
further improvement of treatment results remains an important problem.
 Aim A comparison of the results of standard risk and intermediate risk group regi-
mens ALL-BFM 90 and ALL IC-BFM 2002 was the subject of our study.
 Materials/Methods A retrospective analysis of 41 (18 males and 23 females) children aged 2–15 years 
(median: 6 years) diagnosed from 25.01.1994 to 9.04.1997 and treated accord-
ing to ALL-BFM 90 (group A), and 44 (22 males and 22 females) children aged 
0-18 years (median: 7 years) diagnosed from 12.10.2002 to 31.12.2005 and treat-
ed according to ALL IC BFM-2002 regimen (group B) was performed. For statis-
tical evaluation Kaplan–Meier methods and the log-rank test were used.
 Results Remission on time (day +33) was achieved in 39/41 (94%) children from group A 
and in 43/44 (98%) children from group B (p=0.07). The average day of achiev-
ing remission was 49 (range: 28–109; median: 46) in group A and 39 (range: 
31–71; median: 35) in group B (p<0.001). Treatment failures observed in both 
groups were as follows:
  •  death during induction therapy: 0/41 (0%) – group A, 1/44 (2%) – group B; 
p=0.954;
  • relapse: 2/41 (5%) – group A, 3/43 (7%) – group B; p=1.000;
  • death after relapse: 2/2 (100%) – group A, 0/3 (0%) – group B; p=0.100.
  Probability of 43 months event-free survival (pEFS) was 95.2% in ALL-BFM 90 
and 92.7% in ALL IC-BFM 2002 (p=0.452).
 Conclusions 1.  The average day of achieving remission was signiﬁ cantly shorter in children 
treated according to ALL IC–BFM 2002.
  2.  Although the number of relapses increased, there were no cases of death in 
relapsed patients observed in the ALL IC–BFM 2002 group.
  3.  The follow-up was too short to evaluate the long-term effects of ALL treatment. 
Further observation of investigated groups of patients is necessary.
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BACKGROUND
Acute lymphoblastic leukaemia (ALL) repre-
sents about 30% of cancer in children and thus 
is the most common childhood malignancy. The 
prognosis of ALL has improved greatly over re-
cent decades. More than 95% of patients achieve 
complete remission (i.e. blast cells <5% in the 
bone marrow and disappearance of clinical symp-
toms related to the disease) and about 80% are 
expected to be cured with current chemothera-
py regimens [1–3]. In the ALL-BFM 90 trial the 
standard-risk group (SRG) was deﬁ ned by pred-
nisolone good response (PGR) and initial WBC 
lower than 50 000/μl [4] and the high-risk group 
(HRG) by inadequate response to the cytoreduc-
tive steroid prephase, WBC more than 50 000/μl 
induction failure, or Philadelphia-chromosome-
positive ALL t(9;22) [5] (Table 1). Age, leukocyte 
count, translocations t(9;22) (BCR/ABL) and 
t(4;11) (MLL/AF4), as well as response to pre-
treatment with corticosteroids and to remission-
induction therapy are used for risk group classiﬁ -
cation in children treated according to the ALL 
IC-BFM 2002 protocol (Table 1) [6].
Despite the great progress, further improve-
ment of treatment results remains an important 
problem.
In Poland due to a decision of the Polish Pediatric 
Leukemia/Lymphoma Study Group (PPLLSG), 
between 1993 and 2002, patients from the stand-
ard-risk (SR) group were treated according to 
modiﬁ ed ALL-BFM 90 and from the high-risk 
(HR) group according to the New York regimen 
[7]. The ALL-BFM 90 trial was designed to im-
prove ﬁ nal outcome in patients with childhood 
SR-ALL by using a reduced treatment regimen. 
To achieve this purpose central nervous system 
(CNS) radiotherapy was substainted by high dose 
of methotrexate HD-MTX (3 or 5g/m²) and in-
trathecal therapy [8]. Since December of 2002 
patients have been treated according to ALL 
IC-BFM 2002. This regimen was designed to an-
swer the question whether treatment intensity 
in the newly deﬁ ned standard risk group may be 
safely reduced [9]. The aim was to reduce the risk 
of late complications without decreasing anti-leu-
kaemic effect by adjustment of treatment inten-
sity to risk group. Contrary to the group of pa-
tients treated according to ALL-BFM 90, patients 
treated according to ALL IC-BFM 2002 were ran-
domized. In our study we focused on patients 
from the SR and IR group treated according to 
ALL IC-BFM 2002 to make the group compara-
ble with the standard risk group treated accord-
ing to ALL-BFM 90.
AIM
A comparison of the results of standard risk and 
intermediate risk group regimens ALL-BFM 90 
and ALL IC-BFM 2002 was the subject of our 
study.
MATERIALS AND METHODS 
From 25/01/1994 to 09/04/1997, forty-one chil-
dren (18 males and 23 females) with newly diag-
nosed SR-ALL were treated according to standard 
risk modiﬁ ed ALL-BFM 90 (Figure 1). Median age 
at diagnosis was 6 years, range 2–15 years.
Between 12/10/2002 and 31/12/2005 forty-four 
patients with ALL (22 males and 22 females) aged 
between 1 and 18 years (median: 7 years) were 
treated according to the standard (SR) and inter-
mediate risk (IR) arm of the ALL IC-BFM 2002 
protocol. All children were diagnosed and treat-
ed in the Department of Pediatric Hematology, 
Oncology and Transplantology, Poznań University 
of Medical Sciences. Tables 2 and 3 show the com-
parison of prognostic criteria in patients treated ac-
cording to ALL-BFM 90 and ALL IC-BFM 2002 pro-
tocols and patient characteristics, respectively.
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The outlines of protocols ALL-BFM 90 and ALL 
IC-BFM 2002 are presented in Figures 1 and 2. 
In the ALL-BFM 90 protocol all patients quali-
ﬁ ed for SRG therapy receive induction protocol 
I, consolidation/ extracompartmental protocol 
M, reinduction (delayed intensiﬁ cation) proto-
col II, and maintenance therapy. Patients treated 
according to the ALL IC-BFM 2002 protocol who 
did not qualify for HRG therapy were stratiﬁ ed 
into standard- and intermediate-risk groups. Both 
groups received protocols I and mM at ﬁ rst and 
then were randomized to the newly investigated 
treatment group or control group with known 
performance and outcome (Figure 2).
Also there were differences of drug dosages in each 
trial. In ALL IC-BFM 2002, during induction, dauno-
rubicyn was given only twice at a dose of 30mg/m² 
for SRG BCP-ALL patients. The L-asparaginase dose 
was decreased from 10 000U/m² (in ALL-BFM 90) 
to 5000U/m² (in ALL IC-BFM 2002). In protocol 
mM of ALL IC-BFM 2002, intravenous methotrex-
ate was given at a dose of 2g/m²/24h. Patients from 
SRG and IRG received lower doses of cyclophospha-
mide (500mg/m²) during reinduction. Preventive 
CNS irradiation was given not only to patients who 
initially had CNS disease, but also to all patients with 
T-ALL, while according to ALL-BFM 90, CNS radi-
otherapy in such patients was omitted [9]. These 
differences are presented in Table 3.
Risk group ALL-BFM 90 ALL IC-BFM 2002
Standard risk • for ALL except B-ALL
• age of patients >1 year and <18 years
• WBC <50 000/μl
• PGR*
• age of patients >1 year and <6 years
• WBC <20 000/μl
• <1000 blasts/μl on day 8 of treatment
Intermediate risk — •  age of patients <1 year and >6 years and/or WBC 
>20 000/μl
• <1000 blasts/μl on day 8 of treatment
High risk • WBC >50 000/μl
• PPR**
• translocation t(9;22) [bcr/abl] or t(4;11) [MLL/AF4]
• >1000 blasts/μl on day 8 of treatment
• on day 33 of treatment bone marrow M2 or M3
Table 1. Prognostic criteria and risk groups of children with ALL treated according to ALL-BFM 90 and ALL IC-BFM 2002 protocols.
* PGR – prednisolone good responders (number of blasts in blood <1000/μl on day +8 of induction);
** PPR – prednisolone poor responders (number of blasts in blood >1000/μl on day +8 of induction).
M2 – 5–25% of leukaemic blasts in bone marrow; M3 – more than or equal to 25% of leukaemic blasts in bone marrow.
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Figure 1. Outline of ALL-BFM 90 protocol [10].
Table 2. Characteristics of patients.
Patients
Treatment protocol
ALL-BFM 90 ALL IC-BFM 2002
Number 41 44
Sex 18 males and 23 females 22 males and 22 females
Age range 2–15 years 1–18 years
Mean age 7 years 8 years
Median age 6 years 7 years
Risk group SRG- SRG-; IRG- 
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Range and mean day of ﬁ rst complete remission 
(CR) achievement were assessed. In addition, oc-
currence of ALL relapse and probability of event-
free survival (pEFS) at 43 months were analyzed 
and compared in both study groups. The dura-
tion of event-free survival (EFS) was deﬁ ned as 
the time from diagnosis until the date of treat-
ment failure (induction failure, relapse, non-re-
lapse death).
For statistical evaluation Kaplan-Meier meth-
ods and the log-rank test were used. For bi-vari-
able analysis alpha error probability of 0.05 was 
adopted. Data were processed and analyzed us-
ing Statistica software version 6.0.
RESULTS
Tables 4 and 5 show time of ﬁ rst CR, occur-
rence of relapses and pEFS at 43 months. In 
the ALL-BFM 90 group time of observation 
was 5–43 months (mean: 21 months, medi-
an: 21 months) and in the ALL IC-BFM 2002 
group 6–43 months (mean: 23 months, medi-
an: 22 months).
Remission induction
In the group treated according to modiﬁ ed 
ALL-BFM 90 94% (39 out of 41 children) 
achieved remission on time, day +33 while in the 
Phase of treatment ALL-BFM 90 ALL IC-BFM 2002
Induction
 Daunorubicin (DNR) for all patients 30 mg/m2 (4 times) only in BCP-ALL patients 30 mg/m2 (2 or 4 times)
 L-asparaginase (ASP) 10 000 U/m2 (8 times) 5000 U/m2 (8 times)
Consolidation
Methotrexate (MTX) I.V. 3 g/m2/24h 2 g/m2/24h
Reinduction
Cyclophosphamide (CPM) for all patients
1000 mg/m2
for SR-2 and IR-2 group
500 mg/m2
Maintenance therapy
Methotrexate (MTX) I.T. 4 times for all patients: 
8 mg (patients 1–2 years old)
10 mg (patients 2–3 years old)
12 mg (patients above 3 years old)
in SR-1 and IR-1 group
4 times for BCP-ALL patients: 
8 mg (patients 1-2 years old)
10 mg (patients 2-3 years old)
12 mg (patients above 3 years old)
Vincristine (VCR)
Prednisolone (PRED)
4 times not given
Cranial irradiation in patients with CNS involvement in patients with T-ALL and patients with CNS 
involvement
Table 3. Diff erences between ALL-BFM 90 protocol and ALL IC-BFM 2002 treatment arm for SRG- and IRG-patients with ALL.
Figure 2. Outline of ALL IC-BFM 2002 protocol [9].
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ALL IC-BFM 2002 treatment group the remission 
induction rate was 98% (43 out of 44 children).
Time of remission achievement
The mean day of I CR achievement was 49 (median: 
46) and 39 (median: 35) in patients treated accord-
ing to ALL-BFM 90 and ALL IC-BFM 2002, respec-
tively. This difference attained statistical signiﬁ cance 
in analysis by the log-rank test (p<0.01).
One patient from the ALL IC-BFM 2002 group 
did not obtain remission because of early death 
due to Waterhouse–Friedrichsen syndrome, 
whereas there was no death before remission in 
the ALL-BFM 90 group (Table 5).
Relapses and non-relapse deaths
A total of ﬁ ve patients relapsed following initial 
remission. Two patients on ALL-BFM 90 proto-
col suffered bone marrow (BM) relapse at 22 and 
28 months from diagnosis. In the group treated 
according to ALL IC-BFM 2002 protocol, 3 pa-
tients had relapse: 2 had BM relapse at 4 and 6 
months, and 1 suffered from combined bone 
marrow/central nervous system relapse at 34 
months from diagnosis. Of those patients, both 
from the ﬁ rst group died due to progression of 
the disease.
None of the patients died in ﬁ rst CR from com-
plications in both compared groups.
Event-free survival
After 43 months of observation, the estimate prob-
ability of event-free survival (pEFS) was 95.2% for 
patients treated according to ALL-BFM 90 and 
92.7% for patients from the ALL IC-BFM 2002 
group (p=0.452) (Table 5).
CONCLUSIONS 
One major focus of designing new trials for ALL 
therapy is to answer the question whether risk of 
early and late therapy related complications may 
be reduced while having the same anti-leukae-
mic effect. On protocols ALL-BFM 90 and ALL 
IC-BFM 2002, patients are classiﬁ ed to different 
risk groups by applying new criteria. Some dos-
es of drugs have been decreased in an effort to 
reduce side effects in children treated for ALL. 
The most important changes were: reduction of 
methotrexate dose in consolidation therapy and 
decrease of L-asparaginase during induction ther-
apy in ALL IC-BFM 2002. As a result of all these 
modiﬁ cations there are differences in treatment 
results between ALL-BFM 90 and ALL IC-BFM 
2002. In children with SR-ALL and IR-ALL the 
mean day of remission achievement was signiﬁ -
cantly shorter in those treated according to ALL 
IC-BFM 2002. This is especially important be-
cause of the fact that remission induction is the 
most important prognostic factor in childhood 
ALL. In contrast to deaths observed in relapsed 
patients from the ALL-BFM 90 group, there was 
ALL-BFM 90 (n=41) ALL IC-BFM 2002 (n=44) P
First CR on day +33 39/41 (94%) 43/44 (98%) 0.07
Mean day of fi rst complete remission achievement 49 39 <0.01
Range of days of achieving fi rst complete remission 28–109 31–71 –
Table 4. Time of fi rst complete remission achievement in patients with ALL treated according to ALL-BFM 90 and ALL IC-BFM 2002.
Events ALL-BFM 90 (n=41) ALL IC-BFM 2002 (n=44) P
Death during induction therapy  0/41 (0%)  1/44 (2%) 0.954
Relapse  2/41 (5%)  3/43 (7%) 1.000
Death due to ALL progression  2/2 (100%)  0/3 (0%) 0.000
Death in fi rst continuous complete remission  0/41 (0%)  0/43 (0%) 1.000
pEFS at 43 months 95.2% 92.7% 0.452
Table 5. Treatment results in SRG-patients treated according to ALL-BFM 90 and SRG- and IRG-patients ALL IC-BFM 2002.
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no death in patients demonstrating relapse in the 
ALL IC-BFM 2002 group. This could be the result 
of both better trials for relapses of ALL and the 
possibility of haematopoietic stem cell transplan-
tation (HSCT) in this group of patients. Overall, 
event-free survival at 43 months for the standard 
risk group ALL-BFM 90 was 95.2% in ALL-BFM 
90 and 92.7% in the standard risk and interme-
diate risk ALL IC-BFM 2002 group.
DISCUSSION
The results of pEFS for patients treated accord-
ing to ALL-BFM 90 are comparable with other 
authors, but the follow-up was short and the long-
term effects cannot be evaluated. Some patients 
are still continuing the therapy. Further observa-
tion of the investigated groups of patients is nec-
essary. This is especially important in the context 
of the high rate of cure in children with ALL.
Because of the short time of observation it is dif-
ﬁ cult to compare our results with other recent 
studies.
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